New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - measles vaccine 1000 tcid50 - suspension for injection - 1000 tcid50 - active: measles vaccine 1000 tcid50 excipient: alanine arginine hydrochloride asparagine aspartic acid cysteine cysteine hydrochloride monohydrate dextran 70 glutamic acid glycine histidine isoleucine leucine lysine hydrochloride methionine neomycin sulfate phenolsulfonphthalein phenylalanine proline serine sorbitol threonine tryptophan tyrosine urea valine water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (at end of expiry); mumps vaccine 12500 tcid50 (at end of expiry); rubella vaccine 1000 tcid50 (at end of expiry) - suspension for injection - active: measles vaccine 1000 tcid50 (at end of expiry) mumps vaccine 12500 tcid50 (at end of expiry) rubella vaccine 1000 tcid50 (at end of expiry) excipient: dibasic potassium phosphate dibasic sodium phosphate monohydrate eagle minimum essential medium gelatin medium 199 monobasic potassium phosphate monobasic sodium phosphate monohydrate monosodium glutamate neomycin phenolsulfonphthalein sodium bicarbonate sorbitol sucrose water for injection - m-m-r ii is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - measles vaccine 1000 tcid50; mumps vaccine 5000 tcid50; rubella vaccine 1000 tcid50 - suspension for injection - active: measles vaccine 1000 tcid50 mumps vaccine 5000 tcid50 rubella vaccine 1000 tcid50 excipient: albumin dibasic potassium phosphate glutamic acid lactose monohydrate monobasic potassium phosphate neomycin sulfate phenolsulfonphthalein potassium hydroxide sodium bicarbonate water for injection water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - measles vaccine, schwarz strain 1000 tcid50 (live attenuated) - suspension for injection - 1000 tcid50 - active: measles vaccine, schwarz strain 1000 tcid50 (live attenuated) excipient: amino acids lactose monohydrate mannitol neomycin sulfate sorbitol water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (edmonston b strain (3 log per dose)); mumps virus, jeryl-lynn strain 19952 tcid50 (b level (4.3 log per dose)); rubella virus, wistar ra27/3 strain 1000 tcid50 ((3 log per dose) ); varicella vaccine 9772 pfu (oka/merck strain (3.99 log per dose));   - injection with diluent - 0.5 ml - active: measles vaccine 1000 tcid50 (edmonston b strain (3 log per dose)) mumps virus, jeryl-lynn strain 19952 tcid50 (b level (4.3 log per dose)) rubella virus, wistar ra27/3 strain 1000 tcid50 ((3 log per dose) ) varicella vaccine 9772 pfu (oka/merck strain (3.99 log per dose))   excipient: dibasic potassium phosphate dibasic sodium phosphate gelatin minimum essential medium eagle medium 199 monosodium glutamate phenolsulfonphthalein potassium chloride sodium bicarbonate sodium chloride sorbitol sucrose urea water for injection - proquad is indicated for vaccination against measles, mumps, rubella, and varicella in individuals 12 months through 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - measles vaccine, schwarz strain 1000 tcid50; mumps virus, urabe am 9 strain 2000 tcid50 - solution for injection - 1000/2000tcid50 - active: measles vaccine, schwarz strain 1000 tcid50 mumps virus, urabe am 9 strain 2000 tcid50

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - measles vaccine, schwarz strain 1000 tcid50; mumps virus, urabe am 9 strain 5000 tcid50; neomycin sulfate 25ug; rubella virus, wistar ra27/3 strain 1000 tcid50 - solution for injection - active: measles vaccine, schwarz strain 1000 tcid50 mumps virus, urabe am 9 strain 5000 tcid50 neomycin sulfate 25ug rubella virus, wistar ra27/3 strain 1000 tcid50

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - measles virus, edmonston zagreb 19 strain 1000 tcid50; mumps virus, rubini strain 5000 tcid50; rubella virus, wistar ra27/3 strain 1000 tcid50 - suspension for injection - 1000/5000/1000tcid50 - active: measles virus, edmonston zagreb 19 strain 1000 tcid50 mumps virus, rubini strain 5000 tcid50 rubella virus, wistar ra27/3 strain 1000 tcid50 excipient: albumin arginine hydrochloride calcium gluconate monohydrate lactose monohydrate sodium bicarbonate sodium hydroxide sorbitol water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - rubella virus, quantity: 1000 tcid50; measles virus, quantity: 1000 tcid50; mumps virus, quantity: 12500 tcid50 - injection, powder for - excipient ingredients: hydrolysed gelatin; sorbitol; neomycin; phenolsulfonphthalein; monobasic potassium phosphate; sodium bicarbonate; monosodium glutamate monohydrate; dibasic potassium phosphate; sucrose; monobasic sodium phosphate; dibasic sodium phosphate; glucose monohydrate; sodium chloride; potassium chloride; magnesium sulfate heptahydrate; ferric nitrate nonahydrate; dibasic sodium phosphate dihydrate; sodium pyruvate; folic acid; calcium pantothenate; inositol; choline chloride; nicotinamide; pyridoxine hydrochloride; thiamine hydrochloride; riboflavine; cystine; tyrosine; arginine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; glutamine; calcium chloride dihydrate; water for injections; ascorbic acid; polysorbate 80; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; histidine hydrochloride; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; menadione; nicotinic acid; aminobenzoic acid; pyridoxal hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - m-m-r ii is indicated for simultaneous immunisation against measles, mumps and rubella.,refer to the nhmrc australian immunisation handbook (aih) for vaccination recommendations and schedule.,there is some evidence to suggest that infants immunised against measles at less than 12 months of age, or who are born to mothers who had wild-type measles and who are vaccinated at less than one year of age may not develop sustained antibody levels when later revaccinated. the advantage of early protection must be weighed against the chance for failure to respond adequately on reimmunisation.,infants who are less than 12 months of age may fail to respond to one or more components of the vaccine due to presence in the circulation of residual antibodies of maternal origin, the younger the infant, the lower the likelihood of seroconversion. in geographically isolated or other relatively inaccessible populations for whom immunisation programmes are logistically difficult, and in population groups in which wild-type measles infections may occur in a significant proportion of infants before 15 months of age, it may be desirable to give the vaccine to infants at an earlier age. infants vaccinated under these conditions at less than 12 months of age should be revaccinated after reaching 12 to 15 months of age.,previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women should receive live attenuated rubella vaccine to reduce the risk of exposure of the pregnant woman.,non-pregnant adolescent and adult females: immunisation of susceptible non-pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine is indicated if certain precautions are observed (see 4.4 special warnings and precautions for use and 4.6 fertility, pregnancy and lactation). vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which in turn prevents infection of the foetus and consequent congenital rubella injury. congenital malformations do occur in up to seven percent of all live births, and their chance appearance after vaccination should be borne in mind.,women of childbearing age should be advised not to become pregnant for one month after vaccination against rubella (which is included in m-m-r ii) and should be informed of the reasons for this precaution (see 4.6 fertility, pregnancy and lactation, use in pregnancy).,the australian immunisation handbook recommends that effort should be made to identify and immunise non-pregnant seronegative women of child-bearing age.,women of childbearing age who are potential candidates for vaccination can have serologic tests to determine susceptibility to rubella. however, rubella vaccination of a woman who is not known to be pregnant and has no history of vaccination is justifiable without serologic testing. please refer to aih for recommendations for further information regarding serological testing for immunity to rubella.,postpubertal females should be informed of the frequent occurrence of generally self-limited arthralgia and/or arthritis beginning 2 to 4 weeks after vaccination against rubella (see 4.8 adverse effects (undesirable effects)).,post-partum women it has been found convenient in many instances to vaccinate rubella-susceptible women in the immediate postpartum period using an appropriate rubella-containing vaccine. (see 4.6 fertility, pregnancy and lactation, use in lactation).,revaccination children vaccinated when younger than 12 months of age should be revaccinated at 12 to 15 months of age. persons who were vaccinated originally when 12 months of age or older should be revaccinated with a mmr-containing vaccine, as per the recommended vaccination schedule. revaccination is intended to seroconvert those who did not respond to the first dose. however, data on long term persistence of antibodies are limited and continued surveillance will be required to allow firm recommendations to be made on revaccination. however, persons should be revaccinated if there is evidence to suggest that initial immunisation was ineffective.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - measles virus (schwarz strain) (live attenuated); mumps virus (rit 4385 strain) (live attenuated); rubella virus (ra27/3 strain) (live attenuated) - injection, powder, for solution - min 1000 tcid50 - measles virus (schwarz strain) (live attenuated) min 1000 tcid50; mumps virus (rit 4385 strain) (live attenuated) min 5000 tcid50; rubella virus (ra27/3 strain) (live attenuated) min 1000 tcid50